The following individuals have indicated the following relevant financial relationships with an ACCME-defined ineligible company, also known as a commercial interest:
| Name | Credential | Role | Company | Relationship |
|---|---|---|---|---|
| Amish Dave | MD | Planning committee | Sanofi | Educational Conference |
| Jeff Peterson | MD | Planning committee | Horizon / Amgen | Speaker / Advisor / PI / IP |
| Abbvie | Advisor | |||
| Eli Lilly | Advisor / Speaker / PI | |||
| Novartis | Advisor | |||
| UCB | Advisor | |||
| Phil Mease | MD | Speaker | AbbVie | Research Grant, Speaker, Consulting Fee |
| Acelyrin | Research Grant, Consulting Fee | |||
| Aclaris | Consulting Fee | |||
| Alumis | Consulting Fee | |||
| Amgen | Research Grant, Speaker, Consulting Fee | |||
| Boeringer Ingelheim | Consulting Fee | |||
| Bristol Myers Squibb | Research Grant, Consulting Fee | |||
| Eli Lilly | Research Grant, Speaker, Consulting Fee | |||
| Genascence | Research Grant | |||
| Immagene | Consulting Fee | |||
| Janssen | Research Grant, Speaker, Consulting Fee | |||
| Moonlake | Consulting Fee | |||
| Novartis | Research Grant, Speaker, Consulting Fee | |||
| Pfizer | Research Grant, Speaker, Consulting Fee | |||
| Takeda | Consulting Fee | |||
| UCB | Research Grant, Speaker, Consulting Fee | |||
| Ventyx | Consulting Fee | |||
| Christian Lood | MD | Speaker | Gilead Sciences | Research Funds |
| Boeringer Ingelheim | Research Funds | |||
| Amytryx | Research Funds | |||
| Horizon Therapeutics | Research Funds | |||
| Pfizer | Research Funds | |||
| Redd Pharma | Research Funds, Stock Options | |||
| Eli Lilly | Research Funds | |||
| Citryll | Consulting Fee | |||
| Exagen | Consulting Fee | |||
| Jeff Sparks | MD | Speaker | Bristol Myers Squibb | Consulting Fee, Research Funds |
| AbbVie | Consulting Fee | |||
| Amgen | Consulting Fee | |||
| Boeringer Ingelheim | Consulting Fee | |||
| Gilead Sciences | Consulting Fee | |||
| Janssen | Consulting Fee | |||
| Pfizer | Consulting Fee | |||
| Recor | Consulting Fee | |||
| Sobi | Consulting Fee | |||
| UCB | Consulting Fee |
All relevant financial relationships have been mitigated. All others in control of content have indicated no relevant financial relationships with ACCME-defined commercial interests. All clinical content presented will be evidence-based and unbiased.
